Psychiatric Annals

CME PRE-TEST

Abstract

HOW TO OBTAIN CME CREDITS BY READING THIS ISSUE

The following articles and tests are designed to provide psychiatrists with continuing medical education opportunities. Category 1 credits can be earned by reading the material and successfully answering the quiz. Complete instructions are given below.

To assist you in studying the material, the Pre-Test at the front of the issue indicates some of the areas to be covered, and will enable you to challenge your present knowledge of these subjects before reading further.

EDUCATIONAL OBJECTIVES

Schizophrenia remains the most serious chronic illness in psychiatry. In this issue of Psychiatric Annals, recent genetic, epidemiologic, and brain imaging studies are reviewed with attention to their possible etiological implications for the disease. In addition, modern methods of pharmacologic, social, and rehabilitative treatment are discussed.

PRETEST

1. The point prevalence rate of schizophrenia is approximately:

A. 1%.

B. 0.5%.

C. 0.2%.

D. 0.1%.

2. The World Health Organization (WHO) studies defined schizophrenia according to:

A. DSM-III.

B. PSE/Catego.

C. DSM-III-R.

D. ICD-10.

3. Benefits of using the lowest effective dose of an antipsychotic include all of the following except:

A. Diminution of side effects.

B. An improvement in the quality of life.

C. Fewer relapses.

D. An increased ability to participate in psychosocial treatment.…

HOW TO OBTAIN CME CREDITS BY READING THIS ISSUE

The following articles and tests are designed to provide psychiatrists with continuing medical education opportunities. Category 1 credits can be earned by reading the material and successfully answering the quiz. Complete instructions are given below.

To assist you in studying the material, the Pre-Test at the front of the issue indicates some of the areas to be covered, and will enable you to challenge your present knowledge of these subjects before reading further.

EDUCATIONAL OBJECTIVES

Schizophrenia remains the most serious chronic illness in psychiatry. In this issue of Psychiatric Annals, recent genetic, epidemiologic, and brain imaging studies are reviewed with attention to their possible etiological implications for the disease. In addition, modern methods of pharmacologic, social, and rehabilitative treatment are discussed.

PRETEST

1. The point prevalence rate of schizophrenia is approximately:

A. 1%.

B. 0.5%.

C. 0.2%.

D. 0.1%.

2. The World Health Organization (WHO) studies defined schizophrenia according to:

A. DSM-III.

B. PSE/Catego.

C. DSM-III-R.

D. ICD-10.

3. Benefits of using the lowest effective dose of an antipsychotic include all of the following except:

A. Diminution of side effects.

B. An improvement in the quality of life.

C. Fewer relapses.

D. An increased ability to participate in psychosocial treatment.

10.3928/0048-5713-19891001-03

Sign up to receive

Journal E-contents